Differential regulation of oestrogen receptor β isoforms by 5′ untranslated regions in cancer

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 8, 2010, Pages 2172-2184

  Smith, Laura ^a   Brannan, Rebecca A ^b   Hanby, Andrew M ^b   Shaaban, Abeer M ^b   Verghese, Eldo T ^b   Peter, Mark B ^a   Pollock, Steven ^a   Satheesha, Sampoorna ^a   Szynkiewicz, Marcin ^a   Speirs, Valerie ^a   Hughes, Thomas A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

5 UTRs; Alternative splicing; Breast cancer; ER ; RNA structure; Translation; UORFs

Indexed keywords

ESTROGEN RECEPTOR BETA; INITIATION FACTOR 4E; ISOPROTEIN;

5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ARTICLE; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

5' UNTRANSLATED REGIONS; ALTERNATIVE SPLICING; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR BETA; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 77957105503     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00867.x     Document Type: Article

References (67)

1. Sommer S, Fuqua S. Estrogen receptor and breast cancer. Semin Cancer Biol 2001, 11:339-52.
2. O'Neill P, Davies M, Shaaban A. Wild-type ERβ1 mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 2004, 91:1694-702.
3. Speirs V. ERβ in breast cancer: good, bad, or still too early to tell. J Pathol 2002, 197:143-7.
4. Moore J, McKee D, Slentz-Kesler K. Cloning and characterization of human ERβ isoforms. Biochem Biophys Res Commun 1998, 247:75-8.
5. Bardin A, Boulle N, Lazennec G. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004, 11:537-51.
6. Galluzzo P, Caiazza F, Moreno S. Role of ERbeta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr Relat Cancer 2007, 14:153-67.
7. Lazennec G. Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 2006, 231:151-7.
8. Stettner M, Kaulfuss S, Burfeind P. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 2007, 6:2626-33.
9. Treeck O, Lattrich C, Springwald A. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 2009, 10.1007/s10549--009-0413--2, DOI
10. Leung Y, Mak P, Hassan S. ERβ isoforms: a key to understanding ERβ signalling. PNAS 2006, 103:13162-7.
11. Zhao C, Matthews J, Tujague M. ERβ2 negatively regulates the transactivation of ERα in human breast cancer cells. Cancer Res 2007, 67:3955-62.
12. Audic Y, Hartley R. Post-transcriptional regulation in cancer. Biol Cell 2004, 97:479-98.
13. Gray N, Wickens M. Control of translation initiation in animals. Annu Rev Cell Dev Biol 1998, 14:399-458.
14. Pain V. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem 1996, 236:747-71.
15. Gebauer F, Hentze M. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol 2004, 5:827-35.
16. Kozak M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 2005, 361:13-37.
17. Morris D, Geballe A. Upstream ORFs as regulators of mRNA translation. Mol Cell Biol 2000, 20:8635-42.
18. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987, 15:8125-48.
19. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 1991, 115:887-903.
20. Pesole G, Mignone F, Gissi C. Structural and functional features of eukaryotic mRNA UTRs. Gene 2001, 276:73-81.
21. Koromilas A, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing initiation factor eIF4E. EMBO J 1992, 11:4153-58.
22. Wek R, Jiang H, Anthony T. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006, 34:7-11.
23. Hughes T. Regulation of gene expression by alternative UTRs. Trends Genet 2006, 22:119-22.
24. Zhang T, Haws P, Wu Q. Multiple variable first exons: a mechanism for cell- and tissue-specific gene regulation. Genome Res 2004, 14:79-89.
25. Hughes T, Brady H. Cross-talk between pRb/E2F and Wnt/β-catenin pathways: E2F1 induces axin2 leading to repression of Wnt signalling and to increased cell death. Exp Cell Res 2005, 303:32-46.
26. Pyronnet S, Imataka H, Gingras A. Human eIF4G recruits mnk1 to phosphorylate eIF4E. EMBO J 1999, 18:270-9.
27. Hughes T, Brady H. Expression of axin2 is regulated by the alternative 5'UTRs of its mRNA. J Biol Chem 2005, 280:8581-8.
28. Shaaban A, Green A, Karthik S. Nuclear and cytoplasmic expression of ERβ1, 2 and 5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008, 14:5228-35.
29. Coleman LJ, Peter MB, Teall TJ. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009, 100:1393-9.
30. Allred D, Harvey J, Berado M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-68.
31. Zhou S, Wang G, Liu C. eIF4E and angiogenesis: prognostic markers for breast cancer. BMC Cancer 2006, 6:231-43.
32. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003, 31:3406-15.
33. Hirata S, Shoda T, Kato J. The multiple untranslated first exons system of the human ERβ gene. J Steroid Biochem Mol Biol 2001, 78:33-40.
34. Gray N, Hentze M. Regulation of protein synthesis by mRNA structure. Mol Biol Rep 1994, 19:195-200.
35. Meijer H, Thomas A. Control of eukaryotic protein synthesis by upstream ORFs in the 5'UTR of an mRNA. Biochem J 2002, 367:1-11.
36. Clemens M. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004, 23:3180-8.
37. Kerekatte V, Smiley K, Hu B. The protooncogene/translation factor eIF4E: a survey of expression in breast carcinomas. Int J Cancer 1995, 64:27-31.
38. Rosenwald I, Hutzler M, Wang S. Expression of eIF4E and eIF2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 2001, 92:2164-71.
39. Poola I, Abraham J, Baldwin K. ERβ4 and β5 are full length functionally distinct ERβ isoforms: cloning from human ovary and functional characterization. Endocrine 2005, 27:227-38.
40. Sugiura H, Toyama T, Hara Y. Expression of ERβ wild-type and its variant ERβ2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 2007, 37:820-8.
41. Vinayagam R, Sibson D, Holcombe C. Association of ERβ2/ERβcx with outcome of adjuvant endocrine treatment for primary breast cancer-a retrospective study. BMC Cancer 2007, 7:131-40.
42. Honma N, Horii R, Iwase T. Clinical importance of ERβ evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008, 26:3727-34.
43. Okumura N, Saji S, Eguchi H. Distinct promoter usage of mdm2 gene in human breast cancer. Oncol Rep 2002, 9:557-63.
44. Sobczak K, Krzyzosiak W. Structural determinants of BRCA1 translation regulation. J Biol Chem 2002, 277:17349-58.
45. Gendra E, Colgan D, Meany B. A sequence motif in the SV40 early core promoter affects alternative splicing of transcribed mRNA. J Biol Chem 2007, 282:11648-57.
46. Russcher H, Dalm V, de Jong F. Associations between promoter usage and alternative splicing of the GR gene. J Mol Encrinol 2007, 38:91-8.
47. Auboeuf D, Dowhan D, Kang Y. Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes. PNAS 2004, 101:2270-4.
48. Auboeuf D, Honig A, Berget S. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 2002, 298:416-9.
49. Nogues G, Kadener S, Cramer P. Transcriptional activators differ in their abilities to control alternative splicing. J Biol Chem 2002, 277:43110-4.
50. Rosonina E, Bakowski M, McCracken S. Transcriptional activators control splicing and 3′-end cleavage levels. J Biol Chem 2003, 278:43034-40.
51. Trinklein N, Aldred S, Saldanha A. Identification and functional analysis of human transcriptional promoters. Genome Res 2003, 13:308-12.
52. Foley E, Jazaeri A, Shupnik M. Selective loss of ERβ in malignant human colon. Cancer Res 2000, 60:245-8.
53. Roger P, Sahla M, Mäkelä S. Decreased expression of ERβ protein in proliferative preinvasive mammary tumors. Cancer Res 2001, 61:2537-41.
54. Skliris G, Munot K, Bell S. Reduced expression of ERβ in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003, 201:213-20.
55. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J. Increased ER beta2 expression during mammary carcinogenesis. Clin Cancer Res 2005, 11:3170-4.
56. Shaaban A, O'Neill P, Davies M. Declining ERβ expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003, 27:1502-12.
57. Saji S, Omoto Y, Shimizu C. Expression of ER betacx protein in ERalpha-positive breast cancer: specific correlation with PgR. Cancer Res 2002, 62:4849-53.
58. Rody A, Holtrich U, Solbach C. Methylation of ERβ promoter correlates with loss of ERβ expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 2005, 12:903-16.
59. Nathan C, Franklin S, Abreo F. Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Laryngoscope 1999, 109:1253-8.
60. Rosenwald I, Chen J, Wang S. Upregulation of protein synthesis initiation factor eIF4E is an early event during colon carcinogenesis. Oncogene 1999, 18:2507-17.
61. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004, 83:249-89.
62. Giard DJ, Aaronson SA, Todaro GJ. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973, 51:1417-23.
63. Nelson-Rees WA, Flandermeyer RR, Hawthorne PK. Distinctive banded marker chromosomes of human tumor cell lines. Int J Cancer 1975, 16:145-50.
64. Marot D, Opolon P, Brailly-Tabard S. The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers. Gene Ther 2006, 13:235-44.
65. Berdichevsky F, Alford D, D'Souza B. Branching morphogenesis of human mammary epithelial cells in collagen gels. J Cell Sci 1994, 107:3557-68.
66. Soule HD, Vazguez J, Long A. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973, 51:1409-16.
67. Cailleau R, Olivé M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 1978, 14:911-5.